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Abstract
Motor neuron disease (MND) is an insidious, fatal disorder that progresses with
the selective loss of anterior horn cells of the spinal column. Over 150 years since it
was first described, various therapeutic approaches have been tested in the quest of
a cure but with little success. Current standard therapy only improves lifespan by a
few months; palliative care is the only option available for patients. Stem cell
therapy is a potent approach for the treatment of this devastating disease. A multi-
tude of vitalizing effects, both paracrine and somatic, a robust safety profile, as well
as ease of availability make a strong case for using these cells for therapeutic
purposes. Coupled with rigorous rehabilitation, this powerful treatment modality
has been shown to slow disease progression, improve quality of life, and increase
survival, along with being well tolerated by amyotrophic lateral sclerosis (ALS)/
MND patients. Compelling preclinical as well as clinical evidence abounds that stem
cells hold great potential as a therapy for ALS/MND. Although not a definitive
solution yet, stem cells have been verified to have slowed and/or halted disease
progression in a subset of ALS/MND patients.
Keywords: motor neuron disease (MND), amyotrophic lateral sclerosis (ALS),
stem cells, stem cell therapy, neurorehabilitation, neuro-regenerative rehabilitation
therapy (NRRT), bone marrow-derived stem cells (BMSCs), bone marrow-derived
mononuclear cells (BMMNCs)
1. Introduction
Motor neuron disease (MND) is a set of heterogeneous, idiopathic neurodegen-
erative syndromes characterized by progressive degeneration of anterior horn cells
of the spinal cord, clinically characterized by weak and wasting musculature, which
is eventually fatal [1]. Diagnosis is confirmed via thorough neuro-electrophysiological
investigations [2]. Crude incidence of ALS/MND is 1.75 (1.55–1.96)/100,000
person-years of follow-up [3]. The male/female ratio is reported to be between
1 and 3 but varies with population and age [4]. The pathophysiology is multifarious
(see Section 3.1), causing poor prognosis to be the major hurdle faced by clinicians
worldwide [5]. Multidisciplinary symptomatic management is the sole option
that can be availed by patients [6]. Pharmacological treatment includes riluzole
(glutamate inhibition) [7], edaravone (effective only in the early stages) [8], and
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Nuedexta (for treating pseudobulbar affect) [9]. Multidisciplinary rehabilitation is
a key in managing secondary complications of the disease [10–12].
Studies worldwide endorse the safety and efficacy of stem cells as a therapeutic
intervention, for a variety of neurological disorders [13–15], including ALS/MND
[16–22]. Stem cells are a potent weapon in the fight against neurodegeneration.
These cells hold the unique capacity to self-renew indefinitely while also giving rise
to differentiated progeny under defined physiological conditions, thus repopulating
damaged tissue [23]. Exercise has also been shown to enhance the mobilization and
recruitment of these cells [24]. Given these properties, harnessing the potential of
stem cells as a therapy to attenuate disease progression for neurodegenerative
disorders, along with customized rehabilitative regimes, has gained traction in
recent years.
2. Stem cells
The defining characteristics [25] of a stem cell are the unique capabilities of the
following:
2.1 Clonogenicity
Stem cells self-renew throughout life, i.e., the cells undergo symmetric division
under defined physiological conditions to produce identical daughter cells and
thereby maintain the stem cell pool in the organism.
2.2 Multilineage differentiation
Under certain physiological conditions, stem cells may differentiate and divide
asymmetrically to yield an identical daughter cell and a nonidentical, specialized
daughter cell that acquires the properties of a cell type specific to a tissue.
2.3 Tissue regeneration
Stem cells have the capacity to renew the tissues that they populate. The body
contains stem cell “niches,” i.e., specific regulatory microenvironments conducive
to the maintenance, proliferation, and differentiation of stem cells [26].
Depending on the source, stem cells are classified as embryonic stem cells
(ESCs), fetal stem cells (FSCs), adult stem cells (ASCs), and induced pluripotent
stem cells (iPSCs). ASCs are further classified into bone marrow stem cells
(BMSCs), umbilical cord stem cells (UCSCs), and adipose tissue-derived stem cells
(ADSCs). ESCs are pluripotent, self-renewing cells derived from the inner mass of
the preimplantation blastocyst [27]. Their most obvious benefit is their
pluripotency. However, ESCs tend to be highly tumorigenic, require considerable
manipulation, and are in the hotbed of ethical debates [28]. FSCs are multipotent
cells obtained from fetal tissues of natural, spontaneous abortuses that undergo in
utero death within a specific gestational age range [29]. Limited supply, high degree
of heterogeneity in the cell viability and cellular composition, and ethical issues
hamper their clinical application [30].
Among ASCs, BMSCs take the lead in stem cell therapy in a wide variety of
neurological disorders owing to their robust safety profile and efficient integration
into host parenchyma [31–33]. Because these are adult cells, these are easily avail-
able and are not tumorigenic. The distinctive advantage of the BMSCs over other
cell types is the lack of ethical issues for acquisition and administration. Currently,
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these comprise the most widely employed therapeutic strategy [19, 22, 31, 34–36].
UCSCs overcome the ethical concerns faced by the ESCs due to the ease of collec-
tion postpartum and minimal processing while posing no risk for the mother or the
child. These cells, however, lose their advantage due to slow engraftment, limited
single-dose availability, and long-term storage issues. Hereditary disorders further
limit the benefits of UCSCs [37]. A minimally invasive subcutaneous accessibility
and isolation procedure and a robust, long-term proliferation capacity outline the
ADSCs’superiority [38, 39]. However, these cells find their limits in the presence of
a highly heterogeneous population [40]. Pluripotent stem cells generated from
cultured adult skin fibroblast cells by “inducing” dedifferentiation of unipotent,
differentiated adult tissue cells by the addition of only a few defined factors are
known as induced pluripotent stem cells [41]. iPSCs circumvent ethical concerns
over the use of human embryos for the generation of cells of a desired tissue.
However, oncogenic factors are used for induction of iPSCs’ phenotype and may
risk spontaneous induction of cancerous phenotypes and genomic instability [42].
3. Stem cells and motor neuron degeneration
3.1 Neuropathology of ALS/MND
Grossly, ALS/MND patients exhibit spinal cord atrophy and, in some cases,
atrophy of cerebral white and gray matter (Figure 1). Some patients who have
concomitant frontotemporal dementia show presence of cortical atrophy in frontal
and temporal cortex. Microscopically, this is characterized by demyelination and
axonal loss (Figure 2) [43–51].
3.2 Mechanism of action of stem cells
The clinical outcomes observed in ALS/MND are currently postulated to be due
to various paracrine and somatic mechanisms that render a neurotrophic effect in
various neurodegenerative diseases (Figure 3).
3.2.1 Paracrine effects
Stem cells confer neuroprotection through various paracrine mechanisms.
Depending on the cellular microenvironment, these cells secrete and regulate a
plethora of neurotrophic factors that are essential for the nervous system, like nerve
growth factor-β (NGF-β, critical for the development and maintenance of the ner-
vous system [52]), ciliary neurotrophic factor (CNTF, promotes neurogenesis [53]),
Figure 1.
The anterior horn of the spinal cord and the precentral gyrus are selectively affected and atrophy in ALS/MND.
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brain-derived neurotrophic factor (BDNF, major role player in neuronal develop-
ment as well as synaptic plasticity [53]), glial cell-derived neurotrophic factor
(GDNF, plays an important role in striatal dopaminergic transport [54]), and
angiopoietin 1 (ANG-1, promotes angiogenesis [55]).
3.2.2 Somatic effects
They also migrate to various tissues by homing strategies and have been shown
to integrate into cells of target tissue.
Figure 2.
Pathophysiology of motor neuron disease is multifaceted. Neuronal and nonneuronal cells like glial cell
dysfunction have been postulated to contribute to the pathophysiology. Oxidative stress and subsequent rise in
intracellular peroxidation, upregulation of astrocytic glutamate, mitochondrial abnormality, immune
dysfunction, excitotoxicity, generalized neuroinflammation due secretion of pro-inflammatory cytokines by
microglia, axonal transport system dysfunction, and synaptic failure are some of the mechanisms that have been
identified. Apart from these mechanisms, abnormal cytoplasmic protein inclusions in patients with ALS have
highlighted genetic causality.
Figure 3.
Stem cells play multifarious roles in mitigating ALS/MND pathology.
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3.2.3 Immunomodulation
These cells exude various beneficial immunomodulatory effects and are capable
of homing onto injured sites, as guided by various chemoattractant pathways [55].
Modification of the exaggerated microglial response by immunomodulatory effects
is also observed. Various secreted neurotrophic factors like connective tissue
growth factor (CTGF), fibroblast growth factor (FGF) 2 and 7, and various inter-
leukins (ILs) are responsible for cell proliferation and cytoprotection. Stem cells
regulate innate and adaptive immune cells through release of soluble factors such as
tumor growth factor (TGF)-β and elevation of regulatory T cells (Tregs) and T-
helper-2 cells (Th2 cells) [56]. Reduced levels of TNF-α, IL-1β, IL-1α, and IL-6 and
increased levels of IL-10 lead to an anti-inflammatory effect on the neural micro-
environment [56–58], enhancing neuronal repair. Soluble factors from stem cells
have been shown to significantly upregulate the expression of glutamate trans-
porters in ALS astrocytes, resulting in enhanced glutamate uptake function. Stem
cells also produce vascular endothelial growth factor (VEGF), hepatic growth factor
(HGF), and insulin growth factor (IGF)-1, which are reported to have
neuroprotective effects [57].
3.2.4 Neurogenesis
Mezey et al. have also shown that in a strain of mice incapable of developing cells
of the myeloid and lymphoid lineages, transplanted adult bone marrow cells
migrated into the brain and differentiated into cells that expressed neuron-specific
antigens [58].
3.2.5 Oligodendrogenesis
Using cell fate tracking techniques, Sasaki and colleagues show that stem cells
can differentiate into an oligodendroglial myelinating phenotype in vivo and repair
demyelinated CNS [59].
3.2.6 Astrogliogenesis
Eglitis and Mezey have demonstrated the ability of hematopoietic stem cells
(HSCs) to differentiate into both astrocytes and microglia in wild-type adult mice
using in situ hybridization [60]. Wislet-Gendebien et al. show that nestin-positive
(but not nestin-negative) mesenchymal stem cells are able to favor the astroglial
lineage in certain stem cell progenitors. They also demonstrate that mesenchymal
stem cells express leukemia inhibitory factor (LIF), CNTF, and BMP2 and BMP4
(bone morphogenic protein) mRNAs-cytokines known to play a role in astroglial
fate decision [61].
3.2.7 Neoangiogenesis
Further secretion of growth factors like vascular endothelial growth factor
(VEGF), fibroblast growth factor (FGF), and brain fibroblast growth factor (bFGF)
leads to neoangiogenesis and upregulation of hormones like erythropoietin [62].
The cascade of events triggered due to these leads to formation of new vessels as
well as improved blood circulation, thus retrieving lost tissue functions. Stem cells
may thus be instrumental in arresting the disease progression through the
abovementioned mechanisms.
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4. Literature review
4.1 Preclinical studies
A wide variety of preclinical studies show that stem cells migrate to and restore
lost function of damaged tissue in ALS/MND. Rodent studies have investigated
different cell types such as mouse ES cells differentiated to neurons expressing
green fluorescent protein (GFP) under the promoter of the motor neuron (MN)-
specific gene hb9, mesenchymal stem cells (MSCs), human bone marrow mesen-
chymal stem cells (hMSCs) obtained from an ALS patient (ALS-hMSCs), human
neural stem cells (hNSCs), human cord blood stem cells (HuCB-MNCs), human
embryonic stem cell-derived motor neuron progenitors (hMNPs), bone marrow
cells (BMCs), mesenchymal stromal (stem) cells (MSCs), human umbilical cord
blood (MNC-hUCB), human fetal spinal neural stem cells (hNSCs), human iPSC-
derived neural progenitors (hiPSNPs), HB1.F3.Olig2 cell (stable immortalized
hNSCs encoding the OLIG2 gene)-derived motor neurons, human amniotic mesen-
chymal stem cells (hAMSCs), glial-rich neural progenitors derived from human
iPSCs, enriched population of embryonic stem cell-derived astrocytes (hES-AS),
and neural progenitor cells secreting GDNF (hNPCGDNF) [63–79].
Primarily, stem cells have been shown to have a vast repertoire of paracrine
effects, including release of neurotrophic factors such as GDNF, BDNF, vascular
endothelial growth factor (VEGF), insulin-like growth factor (IGF)-1, NGF, and
neurotrophin (NT)-3. Stem cells also confer neuroprotection by migrating, effi-
ciently engrafting into target tissue, reducing astrogliosis, and differentiating into
neuroglial cell types. Further, they improve motor performance as measured on
rotarod (test measuring rodent balance, grip strength, endurance, and motor coor-
dination), delay disease pathology, and safely extend survival in ALS rodent models
(see Appendix) [20, 63–79].
A limitation of preclinical models of ALS, however, is the inherent inability to
replicate the sporadic onset of ALS/MND, which constitutes majority of patients in
clinical scenario [79]. Additionally, an obvious drawback is the underrepresentation
of the genomic, anatomical, and physiological complexity of humans by the disease
models, which may preclude the translation of results obtained in preclinical set-
tings to the treatment of ALS patients.
4.2 Clinical studies
4.2.1 Worldwide published data
A systematic review and meta-analysis of clinical studies by Moura et al. [80]
have suggested that stem cell therapy is a promising therapy and highlighted the
need for studies with rigorous methodologies to better understand the efficacy of
these therapies. Table 7 (see Appendix) summarizes the studies reviewed by Moura
et al. and other studies that were published using stem cells as therapy in the past
decade. Nineteen clinical studies are summarized; a variety of cells have been
investigated in clinical settings, such as:
1. Autologous mesenchymal stem cells (intraspinal) [81]
2. Bone marrow-derived hematopoietic progenitor stem cells (intraspinal) [18]
3. Autologous peripheral blood stem (intracerebral) [82]
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4. Autologous bone marrow stem cells (intrathecal) [83]
5. Autologous mesenchymal stem cells (intrathecal and intravenous) [31]
6. Olfactory ensheathing cells (intracerebral) and autologous mesenchymal
stromal cells (intrathecal and intravenous or only intrathecal) [84]
7. Neural stem cells derived from a fetal spinal cord (intrathecal) [85]
8. Mesenchymal stem cells induced to secrete neurotrophic factors
(intramuscular, intrathecal, or both) [86]
9. Autologous bone marrow stem cells (intraspinal) [34]
10. Autologous mesenchymal stem cells (intraspinal) [21]
11. Fetal olfactory ensheathing cells (intracerebral) [19]
12. Fetal-derived neural stem cells (intraspinal) [22]
13. NSI-566RSC (Neuralstem, Inc.), a human neural stem cell (intrathecal) [87]
14. Autologous bone marrow mononuclear cells (intrathecal) [16]
15. Mesenchymal stem cells (intrathecal) [35]
16. Autologous mesenchymal stem cells (intravenous, intrathecal) [88]
17. Autologous bone marrow stem cells (intramedullary) [89]
18. Autologous mesenchymal stem cells (intrathecal) [36]
Overwhelmingly, results point toward a robust safety profile for stem cell treat-
ment in ALS/MND. Stem cell therapy has also proven to be efficacious in mitigating
the hostility of a degenerating prognosis in all these studies (see Appendix). These
data collectively advocate for the safety and efficacy of various types of stem cells
for the treatment of this disease, although small scale; larger clinical trials with
sufficient power are required for clearing the turbid field of ALS/MND therapy.
4.2.2 Our published results
4.2.2.1 Our published protocol for stem cell therapy in ALS/MND
4.2.2.1.1 Pre-intervention procedures
We use intrathecal autologous bone marrow mononuclear cell (BMMNC) trans-
plantation for the treatment of ALS/MND, chosen according to the World Medical
Association Declaration of Helsinki—Ethical Principles for Medical Research
Involving Human Subjects. The ethical approval for the intervention is obtained
from Institutional Ethics Committee (IEC). Our exclusion criteria include the pres-
ence of respiratory distress; thus, the effect of stem cell therapy on such patients
cannot be assessed. Our inclusion criteria involve patients diagnosed as definite or
probable ALS according to revised El Escorial criteria [90]. The procedure is
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explained to the patients in detail, and a written informed consent is obtained.
Patients are thoroughly examined by an experienced team of doctors and therapists.
Pre-surgical routine blood tests, urinalysis, and chest X-ray are carried out for
assessing anesthetic and surgical fitness. About 300 μg of granulocyte colony-
stimulating factor (G-CSF) injections are administrated subcutaneously 48 and
24 hours prior to BMMNC transplantation, as they enhance the mobility of
BMMNCs, stimulates CD34+ cells, and increases their survival as well as multipli-
cation rate [91]. The transplant is then carried out in three steps (Figure 4).
4.2.2.1.2 Bone marrow aspiration
Performed in the operation theater under aseptic conditions, 100–120 ml of bone
marrow is aspirated under local anesthesia from the region of anterior superior iliac
spine and collected in the heparinized tubes.
4.2.2.1.3 Cell separation
Using density gradient centrifugation, stem cells are separated. The cell pellet is
analyzed under a microscope using trypan blue to check for the viability of the cells.
Cell number is counted using Tali cell counter. FACS analysis using CD34 PE
antibody is used for identification of CD34+ cells.
4.2.2.1.4 Cell transplantation
In the operation theater under aseptic conditions, the cells are transplanted intra-
thecally into the cerebrospinal fluid through lumbar puncture between the level of
fourth and fifth lumbar vertebra, using an 18G Touhy needle.
4.2.2.1.5 Posttransplantation
Cell transplantation is followed by standard multidisciplinary rehabilitation includ-
ing physiotherapy, occupational therapy, speech therapy, psychological interven-
tion, aquatic therapy, and dietary advice. This approach is termed as neuro-
regenerative rehabilitative therapy (NRRT). Standard medical treatment was con-
tinued with Rilutor. Tablet lithium was prescribed for 6 weeks for its
neuroprotective properties. Lithium levels were monitored.
Figure 4.
Stem cell therapy protocol at NeuroGen Brain and Spine Institute.
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4.2.2.2 Case series
We have published a retrospective controlled cohort study with a total of 57 ALS
patients that investigates the effects of stem cell therapy, in addition to standard
rehabilitation, lithium, and riluzole [79]. Out of these, 37 patients underwent autol-
ogous BMMNC transplantation, while the remaining 20 did not; these served as
controls. We saw that there was a clinically significant difference of 30.38 months
between the average survival duration of intervention and control groups. Inter-
vention group survived for 87.76 (10.45) months, while controls survived for 57.38
(5.31) months. Patients with the onset of the disease below 50 years of age survived
significantly longer (p = 0.039), while limb symptom onset and co-administration
of lithium improved survival duration in a clinically significant manner [16]. Lith-
ium increases the survival, potency, and target tissue integration of BMSCs [92]. It
has been shown to confer neuroprotection in vitro by enhancing cellular BDNF
[93]. In vivo, lithium has been shown to activate autophagy, normalize mitochon-
drial aberration, and suppress reactive astrogliosis. It also reduces ubiquitinated
protein aggregates and increases the number of spared motor neurons in transgenic
ALS mice [94]. Further, lithium is well tolerated by ALS patients who are on
riluzole, even though it may not be effective by itself for treating ALS. This was
confirmed by two trials: a phase III multicenter, randomized, double-blind,
placebo-controlled trial (LiCALS) by Al-Chalabi et al. [95] and a phase IIb random-
ized, double-blind, placebo-controlled, sequential trial by Verstraete et al. [96].
Taken together, these results suggest that a combination strategy of stem cells and
lithium may have played a pronounced role in the outcomes of this study, summa-
rizes the prognostic factors that influence survival in the intervention group. Youn-
ger age at symptom onset and spinal symptom onset favors longer survival
durations according to our findings. Post intervention, lithium prescription com-
bined with standard riluzole treatment and comprehensive rehabilitation enhances
the effect of cellular therapy (Figure 5 and Table 1).
4.2.2.3 Case reports
A 40-year-old female suffering from ALS for 3 years was given intrathecal
autologous BMMNC transplantation along with riluzole, lithium, and intensive
rehabilitation. The disease progression slowed over 17 months along with improve-
ments in neurological symptoms. de Carvalho et al. have previously reported that
the ALSFRS-R score deteriorates about 17% every 6 months [97]; here, the ALSFRS-
R score dropped only by 8% over 17 months after cell transplantation (Figure 6 and
Table 2) [98].
A 41-year-old female suffering from ALS for 3 years was given intrathecal
autologous BMMNC therapy combined with riluzole, neuro-rehabilitation, and
6 weeks of lithium. Her ALSFRS-R score increased from 29 to 32, and FIM score
increased from 48 to 64. The highlight of this case is halting of disease progression
with symptomatic improvements over a period of 12 months after intervention
(Table 3 and Figure 7).
A 63-year-old man who underwent autologous intrathecal BMMNC transplan-
tation as a therapy in a clinical case of MND followed by multidisciplinary
neurorehabilitation showed improvements in muscle strength, fine motor activities,
fasciculation, cramps, and walking (Table 4). ALSFRS-R score improved from 33 to
37; Berg’s balance score improved from 43 to 50, and 6-minute walk test improved
from 283.8 to 303.6 m. His FIM score remained unchanged at 113. These improve-
ments may be attributed to cellular therapy along with standard treatment and
neurorehabilitation [99].
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Figure 5.
(a) Kaplan-Meier survival analysis comparing the mean survival duration of the intervention (n = 37) and
control group (n = 20) from Sharma et al. [16]. Mean survival duration of patients in the intervention group
was higher than the control group by a clinically significant difference of 30.38 months. (b) Subgroup analysis
of the effect of age of symptom onset on survival duration within the intervention group, from Sharma et al. [16]
shows significantly higher survival of those with an onset of symptoms above 50 years of age (p = 0.039).
(c) Subgroup analysis of the effect of the type of symptom onset (limb vs. bulbar) on survival duration in the
intervention group shows higher survival of patients with limb onset of symptoms by 12.23 months.
(d) Subgroup analysis of the effect of lithium prescription on survival duration within the intervention group
shows a clinically higher survival of 106.73 months of the group prescribed with lithium. This is a clinically
significant difference of 30.90 months as compared to controls, whose average survival was 66.83 months.
Prognostic factor Median survival since symptom onset p-Value
Lithium Given 106.73 (15.69) 0.121
Not given 66.83 (7.52)
Age at symptom onset Below 50 years 113.34 (15.45) 0.039*
Above 50 years 63.02 (7.7)
Type of symptom onset Limb 78.01 (14.23) 0.902
Bulbar 90.24 (13.27)
*Statistically significant (p < 0.05).
Table 1.
Summary of prognostic factors affecting patient survival in the intervention group, from Sharma et al. [16].
Standard deviation is indicated in parentheses.
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Figure 6.
Maintenance of a 40-year-old female ALS patient’s condition over the period of 17 months. Disease progression
in patient (red) was compared using ALSFRS-R with average values obtained from de Carvalho et al. (blue) at
0, 5, 15, and 17 months [97].
Outcome
measures
At assessment
before the first
transplant
At 5 months after the first
transplant (just before the
second transplant)
At 15 months
after the first
transplant
At 17 months
after the first
transplant
ALSFRS-R 36 36 36 33
FIM 113 113 113 113
Table 2.
ALSFRS-R and FIM instrument scores of the patient remain stable as compared to assessment, when followed
up at 5, 15, and 17 months.
Outcome
measures
At assessment
before the first
transplant
At 2 months
after the first
transplant
At 6 months
after the first
transplant
At 9 months
after the first
transplant
At 12 months
after the first
transplant
ALSFRS-R 29 33 34 33 32
FIM 48 72 73 71 64
Table 3.
ALSFRS-R and FIM scores of a 41-year-old female ALS patient measured at assessment and after intervention
(at 2, 6, 9, and 12 months post autologous BMMNC transplantation) depict stark improvement.
Figure 7.
ALSFRS-R and FIM scores were marked at 2, 4, 6, 9, and 12 months for this patient. ALSFRS-R score was
measured across survival duration (in months) to compare the disease progression of this patient with natural
disease progression in ALS, as measured by de Carvalho et al. [97]. The patient’s condition was maintained
over a period of 12 months.
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A 29-year-old female patient with anterior horn cell involvement suffering from
MND for 5 years presented with complaints of sudden onset of weakness in bilateral
lower limbs post pregnancy. Her progressive condition was followed by gradual
involvement of upper limbs also; EMG studies were also suggestive of MND. Her
features were suggestive of pure motor system involvement affecting lower motor
neurons. Post NRRT, she immediately showed clinical and functional
improvements [17].
4.2.2.4 Unpublished data
4.2.2.4.1 Female hormones enhance the neuroprotective benefits of cellular
transplantation in patients with amyotrophic lateral sclerosis (ALS)
The male/female ratio in ALS/MND worldwide points toward a lower incidence in
females as compared to males. We hypothesized that this was due to a
neuroprotective effect conferred by female hormones. In order to investigate this
hypothesis, we designed a cohort study with 40 sequentially recruited ALS patients
(28 males and 12 females) who were treated with stem cell therapy. To study the
effect of reproductive hormones, patients were divided into pre- and postmeno-
pausal women and men below and above 50 years of age.
We saw that percentage survival was highest in the premenopausal women
(100%) followed by men below the age of 50 years (75%), postmenopausal women
(60%), and men above the age of 50 years (45%). The disease progression was also
slowest in the premenopausal women, followed by postmenopausal women, and
men below 50 years of age; it was fastest in men above the age of 50 years
(Table 5).
Outcome measures Pre-first SCT At 6 months post the first SCT
ALSFRS-R 33 37
FIM 113 113
6-minute walk test 283.8 m 303.6 m
Berg’s balance score 43 50
Table 4.
Improvements in outcome measures over a period of 6 months in a 63-year-old male ALS patient. ALSFRS-R,
FIM, and 6-minute walk test were measured. Although not standard, Berg’s balance test was administered to
assess his balance.
Group Mean pre-
ALSFRS-R
Mean post-
ALSFRS-R
Difference Average follow-
up (months)
Percentage
mortality
Premenopausal
females (7)
26 23 3 20 0
Postmenopausal
females (5)
21 14 7 14 40
Males below
50 years of age (16)
25 20 5 10 25
Males above
50 years of age (12)
32 25 7 13 55
Table 5.
Percentage mortalities across the four subgroups in a cohort study.
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4.2.2.4.2 Correlation of testosterone levels with progression of amyotrophic lateral
sclerosis: a cross-sectional study
We conducted an open-label nonrandomized cross-sectional study to interrogate
the relationship of testosterone (TT) with disease progression. We found that 39 of
the total 50 (78%) ALS patients had plasma TT levels lower than the mean levels in
healthy, age-matched control males. We also found a decline in TT levels as the
disease progressed on King’s staging as well as ALSFRS-R (Figure 8). There was a
statistically significant moderate monotonic correlation between ALSFRS-R scores
and King’s staging of patients with plasma testosterone levels (ALSFRS-R: r = +0.33;
Figure 8.
Relationship of testosterone with (a) King’s staging and (b) ALSFRS-R.
Figure 9.
Kaplan-Meier survival curves for control vs. intervention groups in our open-label study with a total of 157
subjects (intervention = 116; control = 41). On an average, the treated group survived for 32 months longer
than the control group (p = 0.026).
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King’s staging: r = 0.35; p = 0.01). Taken together, these results suggest that
reduced testosterone may exacerbate motor neuron loss or cause other
etiopathological dysfunctions that remain to be elucidated.
4.2.2.4.3 Effect of intrathecal application of autologous bone marrow mononuclear cells
on survival duration in ALS
We performed a large, open-label cohort study, which included 157 patients diag-
nosed with ALS from September 2013 to May 2017. About 116 patients who
received cell transplantation (autologous BMMNCs) together with standard treat-
ment formed the treatment group, and 41 patients who received only the standard
treatment formed the control group (Figure 9 and Table 6). We observed that on
an average, the treated group survived for 32 months longer than the control group
(p = 0.026).
Collectively, these findings were indicative of possible neuroprotective benefits
of female reproductive hormones. Prognostic factors that predict improved survival
and retarded disease progression include lithium co-administration, limb onset of
symptoms, younger age of symptom onset, and, most importantly, presence of
female hormones (Figure 10).
Characteristics Intervention Control
Total number of patients 157 116 41
Gender Males 81 30
Females 35 11
Mean age at symptom onset (years) 51  11 53  9
Type of symptom onset Bulbar 26 6
Limb 90 21
Table 6.
Demographic data for an open-label study with 157 participants.
Figure 10.
(a) Subgroup analysis: survival duration was 46 months more in patients with limb onset as compared to
bulbar onset (p = 0.001). Bulbar onset n = 26 patients and limb onset n = 90. (b) Survival duration was
41 months more in patients with age of symptom onset <50 years as compared to symptom onset at/above
50 years (p < 0.000).
14
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5. Conclusion and future directions
Stem cell therapy is a novel, promising modality for the treatment of ALS/MND.
Robust safety profiles, low risk-to-benefit ratio, and ease of access make this
approach a strong contender in the race against ALS/MND. Consistently, autolo-
gous BMMNC therapy has been proven to mitigate disease progression; however,
this response may be dependent on various factors, like age of symptom onset,
gender, hormones, type of onset (limb vs. bulbar), and genetic makeup of the
patient, to name a few. Younger patients—especially premenopausal females—may
respond better to autologous BMMNC therapy. Stem cells combat tissue degenera-
tion via a host of somatic and paracrine mechanisms, including neurogenesis,
astrogliogenesis, neoangiogenesis, and immunomodulation. Multidisciplinary
neurorehabilitation enhances the response to cellular therapy.
Although not a cure yet, a combinatorial approach integrating stem cell therapy,
intensive neurorehabilitation, and current pharmacotherapeutic agents (e.g.,
riluzole, lithium, etc.) may be the best way forward. Studies that interrogate the
genetics of patients and their family are the need of the hour, to enhance response
to treatment and develop diagnostics and biomarkers. Also, the role of reproductive
hormones such as progesterone, estradiol, and testosterone needs to be further
explored. Larger clinical studies with stringent criteria are required to understand
the efficacy of these combined methods in the treatment of ALS/MND. The current
scenario suggests that autologous stem cell therapy can be considered along with
standard treatment in carefully selected patients of ALS/MND.
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Authors, year, country (type
of study, sample size)
Type of cells used (route of
administration)
Results
Mazzini et al. [81], Italy
(clinical trial, 7)
Autologous mesenchymal
stem cells (intraspinal)
Slowing down of the linear decline
of muscular strength was evident in
four patients and improvement in
strength in two patients in proximal
lower limb muscles was observed
Deda et al. [18], Turkey
(clinical trial, 13)
Bone marrow-derived
hematopoietic progenitor stem
cells (intraspinal)
9/13 (69.23%) patients improved as
compared with their preoperative
status, as confirmed by EMG
Martinez et al. [82], Mexico
(controlled clinical trial, 10)
Autologous peripheral blood
stem (intracerebral)
The survival of treated patients was
statistically higher (p = 0.01) than
untreated control patients
Prabhakar et al. [83], India
(clinical trial—pilot study, 10)
Autologous bone marrow stem
cells (intrathecal)
There was no significant
deterioration in ALSFRS-R
composite score from baseline at a
1-year follow-up (p = 0.090). The
median survival post procedure was
18.0 months and median time to 4-
point deterioration was 16.7 months
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Authors, year, country (type
of study, sample size)
Type of cells used (route of
administration)
Results
Karussis et al. [31], Israel
(phase I/phase II clinical
trial, 19)
Autologous mesenchymal
stem cells (intrathecal and
intravenous)
The mean ALSFRS-R score
remained stable during the first
6 months of observation. In 80%
of the patients, FVC values
remained stable or above 70% for a
time of 9 months and remained in
60% of patients at 12 months after
application. Signs of disease
stabilization in some patients during
the first 6 months after the
intervention
Gamez et al. [84], Spain
(observational study, 12)
Olfactory ensheathing cells
(intracerebral) and autologous
mesenchymal stromal cells
(intrathecal + intravenous or
only intrathecal)
No changes in the decline of FVC
and ALSFRS-R compared with the
disease’s natural history were
observed
Riley et al. [85], USA (phase I
safety trial, 12)
Neural stem cells derived from
a fetal spinal cord (intrathecal)
Procedural safety of unilateral and
bilateral intraspinal lumbar
microinjections has been suggested
by the results of this trial
Petrou et al. [86], Israel (open-
label proof-of-concept study,
phase I/phase II and IIa)
Mesenchymal stem cells
induced to secrete
neurotrophic factors
(intramuscular (IM),
intrathecal (IT) or (IT+IM))
Progression rate of the ALSFRS-R
score in the IT (or IT+IM)-treated
patients was reduced from 1.2 to
0.6 ALSFRS-R points/month
(p = 0.052), and the progression rate
of the forced vital capacity reduced
from 5.1% to 1.2%/month during
the 6 months follow-up vs.
pretreatment period
Blanquer et al. [34], Spain
(clinical trial, pilot safety
study, 11)
Autologous bone marrow stem
cells (intraspinal)
7/11 (63.63%) patients remained
stable post procedure
Mazzini et al. [21], Italy
(clinical trial, long-term safety
study, 9)
Autologous mesenchymal
stem cells (intraspinal)
Brain MRI revealed no structural
changes relative to baseline
throughout follow-up. No
deterioration noted in the
psychosocial status as well
Huang et al. [19], China
(controlled pilot study, 35)
Fetal olfactory ensheathing
cells (intracerebral)
7/14 improved; 2/14 remained stable
compared to the entry in the treated
group, while only 1/17 of the
patients remained stable within
control
Glass et al. [22], USA (phase I
clinical trial, 12)
Fetal neural stem cells
(intraspinal)
Patients remained stable and
tolerated the therapy well, as seen in
clinical assessments at 6–18 months
Riley et al. [87], USA (phase I
trial, 15)
NSI-566RSC-a human neural
stem cell (intrathecal)
Cellular delivery to the cervical or
thoracolumbar spinal cord was well
tolerated by the patients
Sharma et al. [16], India
(retrospective controlled
cohort study, 57)
Autologous bone marrow
mononuclear cells
(intrathecal)
Mean survival duration of
intervention was 87.76 months,
which was higher than the control
(57.38 months) or previous
epidemiological studies. Survival
duration was significantly
(p = 0.039) higher in people with
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Authors, year, country (type
of study, sample size)
Type of cells used (route of
administration)
Results
the onset of the disease below
50 years of age. Limb onset and
lithium also showed positive
influence on the survival duration
Oh et al. [35], South Korea
(single open-label phase I
clinical trial, 8)
Mesenchymal stem cells
(intrathecal)
Decline in the ALSFRS-R score was
slow during the 6-month follow-up
period
Rushkevich et al. [88], Belarus
(controlled clinical trial, 10)
Autologous mesenchymal
stem cells (intravenous,
intrathecal)
Evaluation of the 12-month follow-
up revealed slowing down of the
disease progression in 10 patients
Ruiz-López et al. [89], Spain
(phase I clinical trial, 11)
Autologous bone marrow stem
cells (intramedullary)
All 11 patients were 100% stable
Syková et al. [36], Czech
Republic (phase I/phase IIa
prospective, nonrandomized,
open-label clinical trial, 26)
Autologous mesenchymal
stem cells (intrathecal)
A significant reduction/stabilization
was found in ALSFRS-R decline at 3,
6, 9, and 12 months after treatment
All studies demonstrate safety of stem cells, except Glass et al. [22]. Safety in this table does not describe events
unrelated to stem cell therapy.
Table 7.
Significant clinical studies employing stem cell therapy for treatment of ALS/MND, primarily from March
2009 to February 2019.
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